Aerie Pharmaceuticals, Inc.
Symbol: AERI
NASDAQ
15.25
USDTrhová cena dnes
-9.4457
Pomer P/E
0.2147
Pomer PEG
753.62M
MRK Cap
- 0.00%
Výnos DIV
Aerie Pharmaceuticals, Inc. (AERI) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 691.88 | 139.8 | 240.4 | 309.2 | |||||||||||
balance-sheet.row.short-term-investments | 504.72 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.net-receivables | 364.41 | 158.8 | 56 | 38.4 | |||||||||||
balance-sheet.row.inventory | 174.37 | 40.4 | 27.1 | 21.1 | |||||||||||
balance-sheet.row.other-current-assets | 56.18 | 16.6 | 8.3 | 7.7 | |||||||||||
balance-sheet.row.total-current-assets | 1286.84 | 355.6 | 331.8 | 376.3 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 290.73 | 74.1 | 68.3 | 58.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 3.98 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 6.32 | 1.6 | 1.9 | 18.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 301.03 | 75.7 | 70.3 | 76.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.account-payables | 34.5 | 8.3 | 8.8 | 12.8 | |||||||||||
balance-sheet.row.short-term-debt | 18.45 | 4.4 | 4.9 | 5.5 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 1253.65 | 256.3 | 210.4 | 188.7 | |||||||||||
Deferred Revenue Non Current | 275.63 | 64.3 | 50.9 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 164.69 | 48 | 39.9 | 65.4 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 1542.75 | 323.7 | 273.6 | 202 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 101.17 | 26.1 | 15.1 | 17.6 | |||||||||||
balance-sheet.row.total-liab | 2036.03 | 448.7 | 378.1 | 285.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.19 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -4645 | -1153.9 | -1079.1 | -896 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.15 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 4198.8 | 1136.7 | 1103.1 | 1063 | |||||||||||
balance-sheet.row.total-stockholders-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1587.87 | - | - | - | |||||||||||
Total Investments | 508.71 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.total-debt | 1272.1 | 260.6 | 215.3 | 194.2 | |||||||||||
balance-sheet.row.net-debt | 1084.93 | 223.5 | 63.7 | 50.2 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 18.4 | 29.5 | 40.1 | 45.1 | |||||||||||
cash-flows.row.change-in-working-capital | 5.69 | -92.6 | 44.9 | -24 | |||||||||||
cash-flows.row.account-receivables | -9.31 | -12.8 | -17.7 | -35.6 | |||||||||||
cash-flows.row.inventory | -15.16 | -12.1 | -5.2 | -10.3 | |||||||||||
cash-flows.row.account-payables | -7.51 | 21.6 | 16.9 | -270.8 | |||||||||||
cash-flows.row.other-working-capital | 37.68 | -89.2 | 50.9 | 292.7 | |||||||||||
cash-flows.row.other-non-cash-items | -0.53 | 1.2 | -0.7 | 9.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.17 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -165.66 | -132.4 | -116.6 | -165.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 151.88 | 117.5 | 192.9 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -7.8 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -18.3 | -18.2 | 73.2 | -183.2 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -8.3 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 2.42 | 3 | -0.9 | 0.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.96 | 0 | 8.3 | 274.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.38 | 3 | -0.9 | 274.8 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -7.75 | -114.4 | 7.6 | -58.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 187.16 | 37.2 | 151.6 | 143.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 194.92 | 151.6 | 143.9 | 202.8 | |||||||||||
cash-flows.row.operating-cash-flow | 7.17 | -99.2 | -64.7 | -150.4 | |||||||||||
cash-flows.row.capital-expenditure | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.free-cash-flow | 2.64 | -102.4 | -67.8 | -160.4 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 213.94 | 194.1 | 83.1 | 69.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 23.52 | 26.8 | 25.3 | 4.8 | |||||||||||
income-statement-row.row.gross-profit | 190.42 | 167.3 | 57.8 | 65.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 87.57 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.operating-expenses | 217.13 | 213.6 | 213.5 | 252.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 240.65 | 240.5 | 238.8 | 257.4 | |||||||||||
income-statement-row.row.interest-income | 0.88 | 0.1 | 2 | 3 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
income-statement-row.row.ebitda-caps | -3.07 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -23.24 | -45.3 | -155.7 | -187.5 | |||||||||||
income-statement-row.row.income-before-tax | -35.23 | -74.2 | -177.9 | -199.7 | |||||||||||
income-statement-row.row.income-tax-expense | 1.32 | 0.6 | 5.2 | -0.1 | |||||||||||
income-statement-row.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 |
Často kladené otázky
Čo je Aerie Pharmaceuticals, Inc. (AERI) celkové aktíva?
Aerie Pharmaceuticals, Inc. (AERI) celkové aktíva sú 431391000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 69440000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.862.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -2.211.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.385.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.233.
Aká je Aerie Pharmaceuticals, Inc. (AERI) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -74810000.000.
Aký je celkový dlh firmy?
Celkový dlh je 260643000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 213642000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 54093000.000.